In the major histocompatibility identical setting of a marrow transplant, two barriers must be overcome. One is the rejection barrier, or host-versus-graft reaction; the other is the graftversus-host reaction. Both processes are mediated by T lymphocytes, suggesting that agents which were effective in controlling graft-versus-host reactions might also be able to modulate hostversus-graft reactions, thereby allowing minimization of the pretransplant high-dose therapy aimed at myeloablation.
Animal models have demonstrated a dose-response relationship with respect to total body irradiation (TBI) and engraftment. In dogs, a single dose of 920 cGy, corresponding to 1500 cGy fractionated TBI, results in engraftment in virtually all of the animals. When the dose is decreased by 50%, the majority of animals reject their grafts. Using this dose, the addition of prednisone did not enhance engraftment, but cyclosporine given for 5 weeks led to engraftment in all of the animals. When the radiation dose was decreased further to 200 cGy, cyclosporine only allowed engraftment for 3-4 months, after which the grafts were rejected. The combination of methotrexate and cyclosporine resulted in engraftment in 2/5 animals, but the rest rejected.
The novel immunosuppressant, mycophenolate mofetil (MMF), which blocks de novo purine synthesis, was shown to be synergistic with cyclosporine. Using 4 weeks of MMF and 5 weeks of cyclosporine, 11/12 animals successfully established long-term engraftment.
1 After 2 years of observation, mixed donor chimerism was maintained. When the dose of TBI was further decreased to 100 cGy, long-term engraftment did not occur, suggesting a delicate balance between the host and the graft.
To elucidate whether TBI is important for creating marrow space, we irradiated the central lymph node chain from the neck down to the upper abdomen with 450 cGy and then administered MMF and cyclosporine. 2 The hematologic toxicity was mild, with a platelet nadir of 100 000/l and granulocyte nadir of 3000-5000/l. At 6 weeks post transplant, donor cells were present in nonirradiated marrow spaces, suggesting that radiation is not necessary to create space. After 1 year, donor lymphocyte infusions were given to the animals and, within 9 weeks, recipient cells disappeared by PCR, indicating complete allograft. Therefore, an allograft had been established without systemic cytotoxic therapy.
Clinical trials using 200 cGy of total body radiation and HLA-identical allogeneic stem cells along with MMF and cyclosporine have resulted in mixed chimerism initially. Complete chimerism occurs in patients who develop graft-versushost disease. Many of these patients had remissions of their disease. In those patients who did not develop an acute graft- versus-host reaction and who had persistent disease, donor lymphocyte infusions were given.
The graft-versus-leukemia effect may be more easily established using minimal conditioning regimens due to the persistence of host dendritic cells capable of presenting the minor host-specific peptides to the incoming donor T cells. In highdose conditioning regimens, these dendritic populations are probably eliminated with myeloablation.
Candidates for nonmyeloablative transplants include patients who are elderly and could not undergo conventional allogeneic transplant, as well as patients with poor organ function. These studies were undertaken in a collaboration between investigators at Fred Hutchinson Cancer Research Center, University of Washington, Veterans Administration Hospital, Seattle, Stanford University, Palo Alto, City of Hope Medical Center, Duarte, University of Colorado, Denver, University of Leipzig, Germany, and University of Torino, Italy. 3 We treated 88 patients, median age 56 (range 31-72 years), with a regimen of 200 cGy TBI in a single fraction, MMF 15 mg/kg p.o. twice a day days 0 to 27, and cyclosporine 6.25 mg/kg p.o. twice a day days −3 to 35, then tapered. Fiftyfive patients were conditioned with 200 cGy TBI alone, while 33 received, in addition, fludarabine, 30 mg/m 2 on days −4, −3 and −2. Fludarabine was added to (successfully) avert the 18% risk of nonfatal graft rejection seen among early patients given TBI alone. No patients developed alopecia, mucositis, diarrhea, veno-occlusive disease, or other major complications of transplantation. The neutrophil nadir was day 15 and was 300/l. Patients with normal neutrophil counts at the time of transplant had an average nadir of Ͼ1000/l. As a result, infections seldom occurred in these patients. The mean platelet nadir was 60 000/l, and 75% of patients did not require platelet transfusions. About 53% of the patients were treated as outpatients, 16% had 1 or 2 days of hospitalization, and the remainder had a median of 8 days in the hospital. Graft-versushost disease occurred in 47% of patients. Most presented with rash or GI involvement. Thirty percent of patients had grade two, 13% grade three, and 4% grade four graft-versus-host disease, respectively, and most responded to resumption of cyclosporine therapy with or without prednisone.
Using FISH and polymerase chain reaction-based analyses, we were able to demonstrate the rate of engraftment and disease remission. Granulocytes and T lymphocytes were engrafted by day 14, reaching almost 90% and 60%, respectively, by day 28. In one patient with chronic lymphocytic leukemia (CLL), the bone marrow continued to show malignant cells for 6 months and then the malignant clone disappeared. Likewise, two patients with chronic myelogenous leukemia became BCR-ABL negative only after 6-8 months. In yet other patients, it took more than 1 year for disease markers to become negative. Disease regression, therefore, can be prolonged using this regimen.
Thus far, 17 acute myelogenous leukemia patients have been treated on this study. The median age was 60 (range 36-71 years). Of the patients in first remission, seven had CR, so far lasting 5-18 months, and one relapsed after 4.5 months and then died after a conventional second transplant. The one patient in second remission died in relapse at 14 months. The one third-remission patient died in remission due to infection. Of the patients with primary refractory disease, two are in remission at 20 and 23 months; the other relapsed and had a conventional second transplant from which he died.
Initial engraftment was seen in 100% of all patients and nonfatal graft rejection occurred in 16%. The overall transplant-related mortality was 11% and the relapse mortality was 20%. The actual overall survival was 69%; in patients who had detectable disease at the time of transplantation, 42% are in remission and another 18% have decreases in paraproteins or other disease markers. Given the relatively slow rates with which remissions develop (several weeks to Ͼ1 year), it is likely that the percentage of complete remissions will further increase.
The fludarabine/200 cGy TBI regimen was used in 28 HLAmatched unrelated donor transplants. 4 Of seven patients with AML in first CR (n = 1), third CR (n = 2) or primary refractory disease and relapse (n = 4), five are in remission. Graft-versushost disease was seen in 55% of unrelated recipients. Thus, nonmyeloablative allogeneic transplants remain an option for patients who would not otherwise be candidates for conventional allogeneic hematopoietic stem cell transplants. Inclusion of younger patients with CLL, multiple myeloma, or refractory Hodgkin's or non-Hodgkin's lymphoma who have a high transplant-related mortality with conventional regimens should also be considered.
Whereas traditional hematopoietic stem cell allografting has mainly relied on high-dose cytotoxic chemoradiation therapy for eradication of malignancy, the current approach makes use of the allogeneic donors' T lymphocytes for that purpose. Shifting the burden of tumor eradication from cytotoxic agents to the graft-versus-tumor effect opens several future avenues of research.
First, it is possible that the last vestiges of cytotoxic therapy contained in the current regimen, ie, fludarabine and 200 cGy TBI, can be eliminated in the future. This prediction is based on the hypothesis that creation of marrow space by cytotoxic agents is not necessary for successful allografts. Rather, grafts can create space on their own via subclinical graft-versus-host effects. The hypothesis was successfully tested in dogs conditioned only with local radiation to cervical, thoracic, and upper abdominal lymph nodes in which allografts were established in unirradiated marrow and lymph nodes as early as 6 weeks after transplant. 2 The canine findings were verified in human patients with certain T cell deficiencies, such as common variable immunodeficiency, in whom allografts were achieved without conditioning therapy. Thus, allografts in patients with malignant diseases might be accomplished in the future by inducing specific host-versus-graft nonresponsiveness through triggering the host's T cell receptors with donor antigen while simultaneously blocking costimulatory signals through CD28 and CD40L. Studies in mice and dogs have already shown the feasibility of such an approach. 5, 6 Alternatively, host T cells might be specifically eliminated using a monoclonal antibody to the T cell receptor, which is coupled to a short-lived (47 min) ␣-emitting radionuclide, Bismuth-213. Alpha-emitters deposit their considerable energy within a 50-70 micron radius, and cells that have been irradiated do not undergo DNA repair. Thus, long-term radiation damage is not expected to occur. One or more of these approaches could be combined with 'megadoses' of hematopoietic stem cells, shown to overcome engraftment barriers on their own. Avoiding cytotoxic agents in the future is likely to avert the short-and Leukemia long-term sequelae typically associated with hematopoietic cell grafts outside of those from graft-versus-host disease.
Second, it is likely that better ways will be found to harness the graft-versus-host reactions, which are critical for accomplishing the graft-versus-tumor effects sought with nonmyeloablative transplants. One way would be to allow graftversus-host disease to go on until all of the underlying tumor has been eradicated and then to turn it off. This might be achievable by switching the patients' immunosuppression from T cell activation blockade with cyclosporine to an antimetabolite, eg, MMF, or a cell cycle inhibitor, eg, rapamycin. Doing so would allow host antigen signaling through the donor T cell receptor, and this may set the stage for inducing programmed T cell death by costimulatory blockade with CTLA4-Ig or an antibody to CD40L. This way, new recruitment of host-specific donor cytotoxic lymphocytes might be stopped and graft-versus-host disease ended. Another way around the problem of graft-versus-host disease would be to separate it from graft-versus-tumor effects. As more information is being generated on minor histocompatibility antigens, it may become possible to identify those polymorphic alloantigens that are preferentially expressed on tumor cells. Specific alloantigen peptides could be used to prime donor dendritic cells and initiate graft-versus-tumor reactions without necessarily inducing graft-versus-host disease.
Third, once safety and efficacy of nonmyeloablative hematopoietic cell transplantation have been established in older patients with hematological malignancies, this approach at adoptive immunotherapy could conceivably be extended to include younger patients, although this may require phase III comparisons with conventional transplants. Also, the procedure may be effective in the treatment of patients with nonmalignant acquired diseases, eg, autoimmune diseases, and genetic diseases, eg, sickle cell disease, in whom reduction of short-and long-term toxicities of conditioning regimens would be particularly gratifying.
